Country: Canada
Language: English
Source: Health Canada
LIDOCAINE HYDROCHLORIDE
LABORATOIRE AGUETTANT
N01BB02
LIDOCAINE
20MG
SOLUTION
LIDOCAINE HYDROCHLORIDE 20MG
BLOCK/INFILTRATION
15G/50G
Ethical
LOCAL ANESTHETICS
Active ingredient group (AIG) number: 0101280001; AHFS:
APPROVED
2020-06-17
_Lidocaine Hydrochloride Injection _ _Page 1 of 23_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Lidocaine Hydrochloride Injection Sterile Solution, 100 mg / 5 mL (20 mg / mL), Intravenous House Standard Antiarrhythmic C01BB01 Preservative-Free. Single use. Laboratoire Aguettant 1 rue Alexander Fleming 69007 Lyon France Imported and Distributed by: Aguettant Canada Inc. 1470 Peel Suite A-152 Montreal, QC, H3A 1T1 Submission Control No: 234178 Date of Initial Approval: November 04, 2021 _Lidocaine Hydrochloride Injection _ _Page 2 of 23_ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES............................................................................. 2 TABLE OF CONTENTS ................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 3 1 INDICATIONS....................................................................................................... 3 1.1 Pediatrics............................................................................................................... 3 1.2 Geriatrics ............................................................................................................... 3 2 CONTRAINDICATIONS....................................................................................... 3 3 DOSAGE AND ADMINISTRATION .................................................................... 3 3.1 Dosing Considerations ......................................................................................... 3 3.2 Recommended Dose and Dosage Adjustment ................................................... 4 3.3 Administration ....................................................................................................... 4 4 OVERDOSAGE ............................................................................... Read the complete document